JP2024522234A5 - - Google Patents
Info
- Publication number
- JP2024522234A5 JP2024522234A5 JP2023577758A JP2023577758A JP2024522234A5 JP 2024522234 A5 JP2024522234 A5 JP 2024522234A5 JP 2023577758 A JP2023577758 A JP 2023577758A JP 2023577758 A JP2023577758 A JP 2023577758A JP 2024522234 A5 JP2024522234 A5 JP 2024522234A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- antigen
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2108712.7A GB202108712D0 (en) | 2021-06-18 | 2021-06-18 | Novel combination therapies and uses thereof |
| GB2108712.7 | 2021-06-18 | ||
| GB2115119.6 | 2021-10-21 | ||
| GBGB2115119.6A GB202115119D0 (en) | 2021-10-21 | 2021-10-21 | Novel combination therapies and uses thereof |
| PCT/EP2022/066566 WO2022263632A1 (en) | 2021-06-18 | 2022-06-17 | Novel combination therapies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522234A JP2024522234A (ja) | 2024-06-11 |
| JP2024522234A5 true JP2024522234A5 (cg-RX-API-DMAC7.html) | 2025-06-25 |
Family
ID=82321438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577758A Pending JP2024522234A (ja) | 2021-06-18 | 2022-06-17 | 新規な併用療法及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240287199A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4355780A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024522234A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022263632A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120446488B (zh) * | 2025-07-08 | 2025-09-12 | 杭州华得森生物技术有限公司 | 用于多重免疫检测的试剂盒及应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| AU3374795A (en) | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| GB201006096D0 (en) | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
| US10899840B2 (en) * | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| HRP20201334T1 (hr) * | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| JP2020522495A (ja) * | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| US20220241412A1 (en) * | 2019-05-24 | 2022-08-04 | Pfizer Inc. | Combination therapies using cdk inhibitors |
-
2022
- 2022-06-17 JP JP2023577758A patent/JP2024522234A/ja active Pending
- 2022-06-17 WO PCT/EP2022/066566 patent/WO2022263632A1/en not_active Ceased
- 2022-06-17 EP EP22735380.2A patent/EP4355780A1/en active Pending
- 2022-06-17 US US18/567,827 patent/US20240287199A1/en active Pending